KDR and breast carcinoma: Ramucirumab is a humanized monoclonal antibody against the VEGF-binding domain of the VEGFR-2, which is found to be overexpressed in many human breast cancers and seems be an important receptor facilitating VEGF-mediated angiogenesis [38].